Validation of a Genomic Classifier in the NRG Oncology/ RTOG 0521 Phase Ill Trial of Docetaxel with Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer

被引：0
|
作者：
Phillips, R. [1 ]
Proudfoot, J. [2 ]
Davicioni, E. [2 ,3 ]
Spratt, D. E. [4 ]
Feng, F. Y. [5 ]
Simko, J. [6 ]
Den, R. B. [7 ]
Pollack, A. [8 ]
Rosenthal, S. A. [9 ]
Sartor, O. [10 ]
Sweeney, C. [11 ]
Attard, G. [12 ]
Patel, S. I. [13 ]
Hall, W. A. [14 ]
Efstathiou, J. A. [15 ]
Shah, A. B. [16 ]
Hoffman, K. E. [17 ]
Pugh, S. [18 ]
Sandler, H. M. [19 ]
Tran, P. T. [20 ]
机构：
[1] Mayo Clin, Dept Radiat Oncol, Rochester, MN USA
[2] Veracyte Inc, San Diego, CA USA
[3] Univ Hosp Seidman Canc Ctr, Dept Radiat Oncol, Cleveland, OH USA
[4] Case Western Reserve Univ, Cleveland, OH USA
[5] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA USA
[6] UCSF, San Francisco, CA USA
[7] Thomas Jefferson Univ, Dept Radiat Oncol, Sidney Kimmel Med Coll & Ctr Canc, Philadelphia, PA USA
[8] Miami Univ, Dept Radiat Oncol, Sylvester Comprehens Canc Ctr, Miami, FL USA
[9] Sutter Med Grp & Canc Ctr, Sacramento, CA USA
[10] Tulane Univ, New Orleans, LA USA
[11] South Australian Immunogen Canc Inst, Adelaide, SA, Australia
[12] Inst Canc Res, London, England
[13] Univ Alberta, Div Radiat Oncol, Edmonton, AB, Canada
[14] Med ColI Wisconsin, Dept Radiat Oncol, Milwaukee, WI USA
[15] Harvard Med Sch, Dept Radiat Oncol, Boston, MA USA
[16] York Canc Ctr, York, PA USA
[17] Univ Texas MD Anderson Canc Ctr, Dept Breast Radiat Oncol, Houston, TX USA
[18] NRG Oncol Stat & Data Management Ctr, Philadelphia, PA USA
[19] Cedars Sinai Med Ctr, Los Angeles, CA USA
[20] Univ Maryland, Dept Radiat Oncol, Sch Med, Baltimore, MD USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2023年 / 117卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
158
引用
收藏
页码：S34 / S35
页数：2
相关论文
共 50 条
  • [1] Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial
    Rosenthal, Seth A.
    Hu, Chen
    Sartor, Oliver
    Gomella, Leonard G.
    Amin, Mahul B.
    Purdy, James
    Michalski, Jeff M.
    Garzotto, Mark G.
    Pervez, Nadeem
    Balogh, Alexander G.
    Rodrigues, George B.
    Souhami, Luis
    Reaume, M. Neil
    Williams, Scott G.
    Hannan, Raquibul
    Horwitz, Eric M.
    Raben, Adam
    Peters, Christopher A.
    Feng, Felix Y.
    Shipley, William U.
    Sandler, Howard M.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (14) : 1159 - +
  • [2] Adjuvant docetaxel for high-risk localized prostate cancer: Update of NRG Oncology/RTOG 0521
    Sandler, Howard M.
    Karrison, Theodore
    Sartor, A. Oliver
    Gomella, Leonard G.
    Amin, Mahul B.
    Purdy, James
    Michalski, Jeff M.
    Garzotto, Mark
    Pervez, Nadeem
    Balogh, Alexander G.
    Rodrigues, George
    Souhami, Luis
    Reaume, M. Neil
    Williams, Scott
    Hannan, Raquibul
    Jones, Christopher U.
    Horwitz, Eric M.
    Rodgers, Joseph P.
    Feng, Felix Y.
    Rosenthal, Seth A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [3] Basal-luminal subtyping of localized high-risk prostate cancer and benefit of adding docetaxel to definitive radiotherapy with androgen suppression in the NRG Oncology/RTOG 0521 phase III trial
    Phillips, Ryan
    Proudfoot, James A.
    Davicioni, Elai
    Liu, Yang
    Spratt, Daniel Eidelberg
    Feng, Felix Y.
    Simko, Jeff
    Den, Robert Benjamin
    Pollack, Alan
    Rosenthal, Seth A.
    Sartor, A. Oliver
    Sweeney, Christopher
    Attard, Gerhardt
    Patel, Samir
    Straza, Michael Wayne
    Efstathiou, Jason A.
    Shah, Amit
    Rodgers, Joseph P.
    Sandler, Howard M.
    Tran, Phuoc T.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial (vol 37, pg 1159, 2019)
    Rosenthal, Seth A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (17) : 1949 - 1949
  • [5] Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial
    Sartor, Oliver
    Karrison, Theodore G.
    Sandler, Howard M.
    Gomella, Leonard G.
    Amin, Mahul B.
    Purdy, James
    Michalski, Jeff M.
    Garzotto, Mark G.
    Pervez, Nadeem
    Balogh, Alexander G.
    Rodrigues, George B.
    Souhami, Luis
    Reaume, M. Neil
    Williams, Scott G.
    Hannan, Raquibul
    Jones, Christopher U.
    Horwitz, Eric M.
    Rodgers, Joseph P.
    Feng, Felix Y.
    Rosenthal, Seth A.
    EUROPEAN UROLOGY, 2023, 84 (02) : 156 - 163
  • [6] Phase II trial of external radiotherapy, brachytherapy, androgen deprivation and docetaxel chemotherapy for high-risk, localized prostate cancer
    DiBiase, SJ
    Dawson, N
    Kwok, Y
    Kataria, R
    Hussain, A
    Nagda, S
    Bangalore, M
    Amin, P
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (02): : S296 - S297
  • [7] Adjuvant Radiation Therapy, Androgen Deprivation, and Docetaxel for High-Risk Prostate Cancer Postprostatectomy: Results of NRG Oncology/RTOG Study 0621
    Hurwitz, Mark D.
    Harris, Jonathan
    Sartor, Oliver
    Xiao, Ying
    Shayegan, Bobby
    Sperduto, Paul W.
    Badiozamani, Kasra R.
    Lawton, Colleen A. F.
    Horwitz, Eric M.
    Michalski, Jeff M.
    Roof, Kevin
    Beyer, David C.
    Zhang, Qiang
    Sandler, Howard M.
    CANCER, 2017, 123 (13) : 2489 - 2496
  • [8] A secondary analysis of PSA response in NRG Oncology/RTOG 9902: A phase III trial of adjuvant chemotherapy with androgen suppression and radiation for high-risk prostate cancer (CaP).
    Mihalcik, Stephen Andrew
    Regan, Meredith M.
    Rosenthal, Seth A.
    Bubley, Glenn J.
    Pienta, Kenneth J.
    Gomella, Leonard G.
    Grignon, David A.
    Hartford, Alan C.
    Morginstin, Mark S.
    Michalski, Jeff M.
    Rajan, Raghu
    McDonald, Andrew Michael
    Dominello, Michael M.
    Atkins, James Norman
    Jones, Christopher U.
    Moughan, Jennifer
    Sandler, Howard M.
    Kaplan, Irving D.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [9] Validation of the performance of the Decipher biopsy genomic classifier in intermediate-risk prostate cancer on the phase III randomized trial NRG Oncology/RTOG 0126.
    Spratt, Daniel Eidelberg
    Huang, Huei-Chung
    Michalski, Jeff M.
    Davicioni, Elai
    Berlin, Alejandro
    Simko, Jeff
    Efstathiou, Jason A.
    Tran, Phuoc T.
    Thompson, Darby
    Parliament, Matthew
    Dayes, Ian S.
    Correa, Rohann
    Robertson, John M.
    Gore, Elizabeth
    Doncals, Desiree E.
    Vigneault, Eric
    Souhami, Luis
    Karrison, Theodore
    Feng, Felix Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [10] Transcriptome profiling of NRG Oncology/RTOG 9601: Validation of a prognostic genomic classifier in salvage radiotherapy prostate cancer patients from a prospective randomized trial
    Feng, Felix Y.
    Sandler, Howard M.
    Huang, Huei-Chung
    Simko, Jeffry
    Davicioni, Elai
    Nguyen, Paul L.
    Efstathiou, Jason A.
    Dicker, Adam P.
    Dignam, James J.
    Seiferheld, Wendy
    Lukka, Himanshu
    Bahary, Jean-Paul
    Pisansky, Thomas Michael
    Hall, William Adrian
    Shah, Amit I.
    Pugh, Stephanie L.
    Pollack, Alan
    Spratt, Daniel Eidelberg
    Shipley, William U.
    Tran, Phuoc T.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
12345